Nov. 4, 2015, 6:19 PM
- TetraLogic (NASDAQ:TLOG): Q3 EPS of -$0.39 beats by $0.03.
Feb. 26, 2015, 4:49 PM
- TetraLogic (NASDAQ:TLOG): Q4 EPS of -$0.38 beats by $0.01.
- Revenue of $0 misses by $1.13M.
Nov. 5, 2014, 6:25 PM
- TetraLogic (NASDAQ:TLOG): Q3 EPS of -$0.42 misses by $0.08.
TetraLogic Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing novel small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development: Birinapant, and SHAPE. Birinapant is... More
Industry: Diagnostic Substances
Country: United States
Other News & PR